Coinfection with SARS-CoV-2 and Influenza A Virus Increases Disease Severity and Impairs Neutralizing Antibody and CD4 + T Cell Responses

• Published in: Journal of virology 2022-03, Vol.96 (6), p.e0187321
• Main Authors: Kim, Eun-Ha, Nguyen, Thi-Quyen, Casel, Mark Anthony B, Rollon, Rare, Kim, Se-Mi, Kim, Young-Il, Yu, Kwang-Min, Jang, Seung-Gyu, Yang, Jihyun, Poo, Haryoung, Jung, Jae U, Choi, Young Ki
• Format: Article
• Language: English
• Subjects: Animals; Antibodies, Neutralizing; CD4-Positive T-Lymphocytes - immunology; Coinfection - immunology; COVID-19 - immunology; Disease Models, Animal; Humans; Influenza A Virus, H1N1 Subtype - immunology; Mice; Orthomyxoviridae Infections - immunology; Pathogenesis and Immunity; SARS-CoV-2 - immunology; Severity of Illness Index; Virology
• ISSN: 0022-538X; 1098-5514; 1098-5514
• DOI: 10.1128/jvi.01873-21

Given the current coronavirus disease 2019 (COVID-19) pandemic, coinfection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza A virus (IAV) is a major concern for public health. However, the immunopathogenic events occurring with coinfections of SARS-CoV-2 and IAV remain unclear. Here, we report the pathogenic and immunological consequences of SARS-CoV-2 and IAV H1N1 coinfection in the K18-hACE2 transgenic mouse model. Compared with a single infection with SARS-CoV-2 or IAV, coinfections not only prolonged the primary virus infection period but also increased immune cell infiltration and inflammatory cytokine levels in bronchoalveolar lavage fluid leading to severe pneumonia and lung damage. Moreover, coinfections caused severe lymphopenia in peripheral blood, resulting in reduced total IgG, neutralizing antibody titers, and CD4 T cell responses against each virus. This study sheds light on the immunopathogenesis of SARS-CoV-2 and IAV coinfection, which may guide the development of effective therapeutic strategies for the treatment of patients coinfected with these viruses. The cocirculation of influenza virus merging with the COVID-19 pandemic raises a potentially severe threat to public health. Recently, increasing numbers of SARS-CoV-2 and influenza virus coinfection have been reported from many countries. It is a worrisome issue that SARS-CoV-2 coinfection with other pathogens may worsen the clinical outcome and severity of COVID-19 and increase fatality. Here, we evaluated SARS-CoV-2 and IAV coinfection using the K18-hACE2 mouse model. Coinfected mice exhibited increased mortality with prolonged IAV shedding. Furthermore, coinfected mice showed a higher level of cytokines and chemokines than a single infection condition. Interestingly, our data show that coinfected mice showed significantly fewer virus-specific and neutralizing antibodies than the mice with a single infection. Overall, this study suggests that coinfection aggravates viral pathology by impaired neutralizing antibody response.